EP1446155A1 - Composition pharmaceutique comportant des polypeptides du facteur vii et des polypeptides d'aprotinine - Google Patents

Composition pharmaceutique comportant des polypeptides du facteur vii et des polypeptides d'aprotinine

Info

Publication number
EP1446155A1
EP1446155A1 EP02774481A EP02774481A EP1446155A1 EP 1446155 A1 EP1446155 A1 EP 1446155A1 EP 02774481 A EP02774481 A EP 02774481A EP 02774481 A EP02774481 A EP 02774481A EP 1446155 A1 EP1446155 A1 EP 1446155A1
Authority
EP
European Patent Office
Prior art keywords
aprotinin
factor
related polypeptide
factor vii
vll
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02774481A
Other languages
German (de)
English (en)
Inventor
Rasmus Rojkjaer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP1446155A1 publication Critical patent/EP1446155A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to a pharmaceutical composition comprising factor VII or a factor VI l-related polypeptide and aprotinin or a aprotinin-related polypeptide.
  • the invention also relates to the use of a combination of factor VII or a factor Vll-related polypeptide, and a aprotinin or a aprotinin-related polypeptide for the manufacture of a medicament for treatment of subjects suffering from bleeding episodes, or prevention hereof.
  • the invention also relates to a method for treatment of bleeding episodes in subjects and to a method for enhancing clot formation in a subject.
  • the present invention also relates to kits comprising these compounds.
  • Haemostasis is initiated by the formation of a complex between tissue factor (TF) being exposed to the circulating blood following an injury to the vessel wall, and FVIIa which is present in the circulation in an amount corresponding to about 1 % of the total FVII protein mass.
  • This complex is anchored to the TF-bearing cell and activates FX into FXa and FIX into FIXa on the cell surface.
  • FXa activates prothrombin to thrombin, which activates FVIII, FV, FXI and FXIII.
  • the limited amount of thrombin formed in this initial step of haemostasis also activates the platelets. Following the action of thrombin on the platelets these change shape and expose charged phospholipids on their surface.
  • This activated platelet surface forms the template for the further FX activation and the full thrombin generation.
  • the further FX activation on the activated platelet surface occurs via a FIXa-FVIIIa complex formed on the surface of the activated platelet, and FXa then converts prothrombin into thrombin while still on the surface.
  • Thrombin then converts f ibrinogen into fibrin which is insoluble and which stabilizes the initial platelet plug. This process is compartmentalized, i.e., localised to the site of TF expression or exposure, thereby minimizing the risk of a systemic activation of the coagulation system.
  • the insoluble fibrin forming the plug is furthermore stabilised by FXIII-catalysed cross-linking of the fibrin fibres.
  • FVIIa exists in plasma mainly as a single-chain zymogen, which is cleaved by FXa into its two-chain, activated form, FVIIa.
  • Recombinant activated factor Vila (rFVIIa) has been developed as a pro-haemostatic agent.
  • the administration of rFVIIa offers a rapid and highly effective pro- haemostatic response in haemophilic subjects with bleedings who cannot be treated with coagulation factor products due to antibody formation.
  • NovoSeven® Novo Nordisk A/S,Denmark
  • Novoseven® is indicated for treatment of bleeding episodes in haemophilia A and B patients.
  • Novoseven® is the only recombinant FVIIa available on the market for effective and reliable treatment of bleeding episodes.
  • Aprotinin (bovine pancreatic trypsin inhibitor) is a kunitz-type inhibitor, known to inhibit various serine proteases, including trypsin, chymotrypsin, plasmin and kallikrein, and is used therapeutically in the treatment of acute pancreatitis, various states of shock syndrome, hyperfi- brinolytic hemorrhage and myocardial infarction (ycf., for instance, J. E. Trapnell et al, Brit. J. Surg. 61, 1974, p. 177; J. McMichan et al., Circulatory shock 9, 1982, p. 107; L M. Auer et al., Acta Neurochir. 49, 1979, p.
  • aprotinin in high doses significantly reduces blood loss in connection with cardiac surgery, including cardiopulmonary bypass operations (cf., for instance, B. P. Bidstrup et al., J. Thorac. Cardiovasc. Surg. 97, 1989, pp. 364-372; W. van Oeveren et al., Ann. Thorac. Surg. 44, 1987, pp. 640-645). It has previously been demon- strated (cf. H. R. Wenzel and H.
  • aprotinin analogues e.g. aprotinin(1-58, Val15) exhibit a relatively high selectivity for granulocyte elastase and an inhibitory effect on collagenase.
  • Aprotinin (1-58, Ala15) has a weak effect on elastase, while aprotinin (3-58, Arg15, Ala17, Ser42) exhibits an excellent plasma kallikrein inhibitory effect (cf. WO 89/10374).
  • the Kunitz inhibitors are generally basic, low molecular weight proteins comprising one or more inhibitory domains (" Kunitz domains").
  • the Kunitz domain is a folding domain of approximately 50-60 residues, which forms a central anti-parallel beta sheet and a short C- terminal helix. This characteristic domain comprises six cysteine residues that form three disulfide bonds, resulting in a double-loop structure. Between the N-terminal region and the first beta strand resides the active inhibitory binding loop. This binding loop is disulfide bonded through the P2 Cys residue to the hairpin loop formed between the last two beta strands. Isolated Kunitz domains from a variety of proteinase inhibitors have been shown to have inhibitory activity (e.g., Petersen et al., Eur. J. Biochem. 125:310-316, 1996; Wagner et al., Biochem. Biophys. Res. Comm. 186:1138-1145, 1992; Dennis et al., J. Biol. Chem. 270:25411-25417, 1995).
  • inhibitory activity e.g., Petersen et al
  • a major goal in surgery as well as in the treatment of major tissue damage is to avoid or minimise the bleeding.
  • To avoid or minimise such bleeding it is of importance to ensure the formation of stable and solid haemostatic plugs that are not easily dissolved by fibrinolytic enzymes. Furthermore, it is of importance to ensure quick and effective formation of such plugs or clots.
  • European Patent No. 225.160 (Novo Nordisk) concerns compositions of FVIIa and methods for the treatment of bleeding disorders not caused by clotting factor defects or clotting factor inhibitors.
  • European Patent No. 82.182 (Baxter Travenol Lab.) concerns a composition of factor Vila for use in counteracting deficiencies of blood clotting factors or the effects of inhibitors to blood clotting factors in a subject.
  • One object of the present invention is to provide compositions, which can effectively be used in the treatment or prophylaxis of bleeding episodes and coagulation disorders.
  • a second object of the present invention is to provide compositions in single-unit dosage form, which can effectively be used in the treatment or prophylaxis of bleeding episodes or as a procoagulant.
  • Another object of the present invention is to provide compositions, methods of treatment or kits exhibiting a synergistic effect.
  • a further object of the present invention is to provide compositions, methods of treatment or kits exhibiting no substantial side effects, such as a high level of systemic activation of the coagulation system.
  • the invention provides a pharmaceutical composition comprising factor VII or a factor Vll-related polypeptide, and aprotinin or an aprotinin-related polypeptide.
  • the invention provides a kit of parts containing a treatment for bleeding episodes comprising a) An effective amount of a preparation of factor VII or a factor Vll-related polypeptide and a pharmaceutically acceptable carrier in a first unit dosage form; b) An effective amount of a preparation of aprotinin or a aprotinin-related polypeptide and a pharmaceutically acceptable carrier in a second unit dosage form; and c) Container means for containing said first- and second-unit dosage forms.
  • the invention provides the use of factor VII or a factor Vll-related polypeptide in combination with a aprotinin or a aprotinin-related polypeptide for the manufacture of a medicament for treating bleeding episodes in a subject.
  • the invention provides the use of a composition as described in any one of claims 1 to18, for the manufacture of a medicament for treating bleeding episodes in a subject.
  • the medicaments are for reducing time needed to obtain full haemostasis, reducing time needed to maintain haemostasis, reducing clotting time, prolonging the clot lysis time, and increasing clot strength.
  • the medicaments are for treatment of subjects experiencing bleeding episodes due to surgery, trauma, or other forms of tissue damage; coagulophathy, in- eluding coagulopathy in multi-transfused subjects; congenital or acquired coagulation or bleeding disorders, including decreased liver function ("liver disease”); defective platelet function or decreased platelet number; lacking or abnormal essential clotting "compounds” (e.g., platelets or von Willebrand factor protein); increased f ibrinolysis; anticoagulant therapy or thrombolytic therapy; stem cell transplantation.
  • the bleedings occur in organs such as the brain, inner ear region, eyes, liver, lung, tumour tissue, gastrointestinal tract; in another series of embodiments, it is diffuse bleeding, such as in haemorrhagic gastritis and profuse uterine bleeding.
  • the bleeding episodes are bleeding in connection with surgery or trauma in subjects having acute haemarthroses (bleedings in joints), chronic haemophilic arthropathy, haematomas, (e.g., muscular, retroperitoneal, sublingual and retropharyngeal), bleedings in other tissue, haematuria (bleeding from the renal tract), cerebral haemorrhage, surgery (e.g., hepatectomy), dental extraction, and gastrointestinal bleedings (e.g., UGI bleeds).
  • the medicament is for treating bleeding episodes due to trauma, or surgery, or lowered count or activity of platelets, in a subject.
  • the invention provides a method for treating bleeding episodes in a subject, the method comprising administering to a subject in need thereof a first amount of a preparation of factor VII or a factor Vll-related polypeptide, and a second amount of a prepara- tion of aprotinin or a aprotinin-related polypeptide, wherein the first and second amount together are effective to treat bleedings.
  • the invention provides a method for reducing clotting time in a subject, the method comprising administering to a subject in need thereof a first amount of a preparation of factor VII or a factor Vll-related polypeptide, and a second amount of a prepara- tion of aprotinin or a aprotinin-related polypeptide wherein the first and second amount together are effective to reduce clotting time.
  • the invention provides a method to enhance haemostasis in a subject, the method comprising administering to a subject in need thereof a first amount of a preparation of factor VII or a factor Vll-related polypeptide, and a second amount of a prepara- tion of aprotinin or a aprotinin-related polypeptide wherein the first and second amount together are effective to enhance haemostasis.
  • the invention provides a method for prolonging the clot lysis time in a subject, the method comprising administering to a subject in need thereof a first amount of a preparation of factor VII or a factor Vll-related polypeptide, and a second amount of a prepara- tion of aprotinin or a aprotinin-related polypeptide wherein the first and second amount together are effective to prolong the clot lysis time.
  • the invention provides a method for increasing clot strength in a subject, the method comprising administering to a subject in need thereof a first amount of a preparation of factor VII or a factor Vll-related polypeptide, and a second amount of a prepara- tion of aprotinin or a aprotinin-related polypeptide wherein the first and second amount together are effective to increase clot strength.
  • the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide are administered in single-unit dosage form.
  • the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide are administered in the form of a first-unit dosage form comprising a preparation of factor VII or a factor Vll-related polypeptide and a second- unit dosage form comprising a preparation of aprotinin or a aprotinin-related polypeptide.
  • the first-unit dosage form and the second-unit dosage form are administered with a time separation of no more than 15 minutes.
  • the invention provides a kit containing a treatment for bleeding episodes comprising d) An effective amount of factor VII or a factor Vll-related polypeptide, and an effective amount of aprotinin or a aprotinin-related polypeptide, and a pharmaceutically acceptable carrier in a single-unit dosage form; and e) Container means for containing said single-unit dosage form.
  • the factor VII or factor Vll-related polypeptide is a factor Vll-related polypeptide. In one series of embodiments of the invention the factor Vll-related polypeptide is a factor VII amino acid sequence variant. In one embodiment the ratio between the activity of the factor Vll-related polypeptide and the activity of native human factor Vila (wild-type FVIIa) is at least about 1.25 when tested in the "In Vitro Hydrolysis Assay" as described in the present description.
  • the factor VII or factor Vll-related polypeptide is factor VII.
  • said factor VII is human factor VII.
  • the factor VII is bovine, porcine, canine, equine, murine or salmon factor VII.
  • the factor VII is recombinantly made.
  • the factor VII is derived from plasma.
  • the factor VII is recombinant human factor VII.
  • the factor VII or factor Vll-related polypeptide is in its activated form.
  • the factor VII is recombinant human factor Vila.
  • the aprotinin or aprotinin-related polypeptide is an aprotinin-related polypeptide.
  • the aprotinin-related polypeptide is an aprotinin amino acid-sequence variant.
  • the aprotinin-related polypeptide is a Kunitz-type inhibitor polypeptide with aprotinin activity.
  • the ratio be- tween the activity of said aprotinin-related polypeptide and the activity of native human plasma aprotinin (wild-type aprotinin) is at least about 1.25 when tested in the "aprotinin assay" as described in the present description.
  • the aprotinin or aprotinin-related poly- peptide is an aprotinin polypeptide.
  • the aprotinin is bovine aprotinin.
  • the aprotinin is, e.g., porcine, canine, equine, murine or salmon aprotinin.
  • the aprotinin is recombinantly made.
  • the aprotinin is derived from plasma.
  • the aprotinin is recombinant bovine plasma aprotinin.
  • the aprotinin-related polypeptide is a fragment of aprotinin.
  • the aprotinin-related polypeptide is a hybrid aprotinin polypeptide, e.g., a porcine/bovine hybrid.
  • the aprotinin polypeptide is a human aprotinin equivalent.
  • the aprotinin equivalent is an aprotinin amino acid sequence variant with a reduced positive net charge of the protein.
  • the aprotinin polypeptide is a kunitz-type inhibitor domain with aprotinin activity.
  • the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide are present in a ratio by mass of between about 100:1 and about 1 :100 (w/w factor VII:aprotinin).
  • the factor Vll-related polypeptides are amino acid sequence variants having no more than 20 amino acids replaced, deleted or inserted compared to wild- type factor VII (i.e., a polypeptide having the amino acid sequence disclosed in U.S. Patent No. 4,784,950), In another embodiment, the factor VII variants have no more than 15 amino acids replaced, deleted or inserted; in other embodiments, the factor VII variants have no more than 10 amino acids, such as 8, 6, 5, or 3 amino acids, replaced, deleted or inserted compared to wild- type factor VII.
  • the factor VII variants are selected from the list of L305V- FVIIa, L305V/M306D/D309S-FVIIa, L305l-FVIIa, L305T-FVIIa, F374P-FVIIa, V158T/M298Q-FVIIa, V158D/E296V/M298Q-FVIIa, K337A-FVIIa, M298Q-FVIIa, V158D/M298Q-FVIIa, L305V/K337A-FVIIa, V158D/E296V/M298Q/L305V-FVIIa, V158D/E296V/M298Q/K337A-FVIIa, V158D/E296V/M298Q/L305V/K337A-FVIIa, V158D/E296V/M298Q/L305V/K337A-FVIIa, K157A
  • the factor Vll-related polypeptides have increased tissue factor-independent activity compared to native human coagulation factor Vila.
  • the increased activity is not accompanied by changes in the substrate specificity.
  • the binding of the factor Vll-related polypeptides to tissue factor are not impaired and the factor Vll-related polypeptides have at least the activity of wild-type factor Vila when bound to tissue factor.
  • the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide are recombinant human factor Vila and recombinant bovine aprotinin.
  • the clotting time is reduced in mammalian blood.
  • the haemostasis is enhanced in mammalian blood.
  • the clot lysis time is prolonged in mammalian blood.
  • the clot strength is increased in mammalian blood.
  • the mammalian blood is human blood.
  • the mammalian blood is normal human blood; in one embodiment, the blood is blood from a subject having an impaired thrombin generation.
  • the blood is blood from a subject having a deficiency of one or more coagulation factors; in another embodiment, the blood is blood from a subject having inhibitors against one or more coagulation factors; in one embodiment, the blood is from a subject having a lowered concentration of fibrinogen; in one embodiment, the blood is aprotinin-deficient human blood. In one series of embodiments, the blood is plasma.
  • the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide are the sole haemostatic agents contained in the composition. In another embodiment, the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide are the sole active haemostatic agents contained in the composition. In another embodiment, the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide are the sole coagulation factors administered to the subject.
  • the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide are the sole active agents administered to the patient.
  • the composition is substantially free of thrombin or prothrombin; in another embodiment, the composition is substantially free of FX; in another embodiment, the composition is substantially free of FXa.
  • the pharmaceutical composition is formulated for intravenous administration, preferably injection or infusion, in particular injection.
  • the composition contains at least one pharmaceutical acceptable excipients or carrier.
  • the composition is in single-unit dosage form wherein the single-unit dosage form contains both coagulation factors.
  • the composition is in the form of a kit-of-parts comprising a preparation of factor VII or a factor Vll-related polypeptide as a first-unit dosage form and a preparation of aprotinin or a aprotinin-related polypeptide as a second-unit dosage form, and comprising container means for containing said first and second unit dosage forms.
  • the composition or kit as applicable, further contains directions for the administration of the composition or separate components, respectively.
  • the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide are administered in single-dosage form. In one embodiment of the invention, the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide are administered in the form of a first-unit dosage form comprising a preparation of factor VII or a factor Vll-related polypeptide and a second-unit dosage form comprising a preparation of aprotinin or a aprotinin-related polypeptide.
  • the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide are administered simultaneously. In another embodiment, the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin- related polypeptide are administered sequentially. In one embodiment, the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide are administered with a time separation of no more than 15 minutes, preferably 10, more preferred 5, more preferred 2 minutes.
  • the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide are administered with a time separation of up to 2 hours, preferably from 1 to 2 hours, more preferred up to 1 hour, more preferred from 30 minutes to 1 hour, more preferred up to 30 minutes, more preferred from 15 to 30 minutes.
  • the effective amount of the factor VII or factor Vll-related polypeptide is an amount from about 0.05 mg/day to about 500 mg/day (70-kg subject). In one embodiment, the effective amount of a preparation of aprotinin or a aprotinin-related polypeptide is from about 0.01 mg/day to about 500 mg/day (70-kg subject). In one embodiment the factor VII or factor Vll-related polypeptide and aprotinin or aprotinin-related polypeptide are present in a ratio by mass of between about 100:1 and about 1 :100 (w/w factor Vlkaprotinin)
  • the pharmaceutical composition is in single-unit dosage form and consists essentially of a preparation of factor VII or a factor VII- related polypeptide, and a preparation of aprotinin or a aprotinin-related polypeptide, and one or more of the components selected from the list of pharmaceutical acceptable carriers, stabilizers, detergents, neutral salts, antioxidants, preservatives, and protease inhibitors.
  • the pharmaceutical composition is in the form of a kit-of-parts with the first-unit dosage form consisting essentially of a preparation of factor VII or a factor Vll-related polypeptide, and one or more of the components selected from the list of pharmaceutical acceptable carriers, stabilizers, detergents, neutral salts, antioxidants, preservatives, and protease inhibitors; and with the second-unit dosage form consisting essentially of a preparation of aprotinin or a aprotinin-related polypeptide and one or more of the components selected from the list of pharmaceutical acceptable carriers, stabilizers, detergents, neutral salts, antioxidants, preservatives, and protease inhibitors.
  • the subject is a human; in another embodiment, the subject has an impaired thrombin generation; in one embodiment, the subject has a lowered plasma concentration of fibrinogen (e.g., a multi-transfused subject); in one embodiment, the subject has a lowered plasma concentration of factor VIII or FIX.
  • fibrinogen e.g., a multi-transfused subject
  • the subject has a lowered plasma concentration of factor VIII or FIX.
  • the invention concerns a method to enhance haemostasis in a subject suffering from a factor VII responsive syndrome compared to when the subject is treated with factor VII as the only coagulation protein, the method comprising administering to the subject in need thereof a first amount of a preparation of factor VII or a factor Vll-related polypeptide, and a second amount of a preparation of aprotinin or a aprotinin-related polypeptide, wherein the first and second amounts together are effective to enhance haemostasis.
  • the invention concerns a method to enhance formation of thrombin in a subject, the method comprising administering to the subject in need thereof a first amount of a preparation of factor VII or a factor Vll-related polypeptide and a second amount of a preparation of aprotinin or a aprotinin-related polypeptide, wherein the first and second amounts together are effective to enhance formation of thrombin.
  • the invention concerns a method to enhance formation of thrombin in a subject suffering from a factor VII responsive syndrome compared to when the subject is treated with factor VII as the only coagulation protein, the method comprising administering to the subject in need thereof a first amount of a preparation of factor VII or a factor Vll-related polypeptide and a second amount of a preparation of aprotinin or a aprotinin-related polypeptide, wherein the first and second amounts together are effective to enhance formation of thrombin.
  • the invention concerns a method for reducing the number of administrations of coagulation factor protein needed to accomplish haemostasis in a subject suffering from a factor VII responsive syndrome compared to the number of administrations needed when actor VII is administered to the subject as the only coagulation factor protein, the method com- prising administering to a subject in need thereof a first amount of a preparation of factor VII or a factor Vll-related polypeptide and a second amount of a preparation of aprotinin or a aprotinin-related polypeptide, wherein the first and second amounts together are effective to reduce the number of administrations of coagulation factor protein.
  • the invention concerns a method of treating bleedings in a subject suffering from a factor VII responsive syndrome, the method comprising administering to the subject in need thereof a first amount of a preparation of factor VII or a factor Vll-related polypeptide and a second amount of a preparation of aprotinin or a aprotinin-related polypeptide, wherein the first and second amounts together are effective in treating bleedings.
  • the factor VII is human recombinant factor Vila (rFVIIa).
  • the rFVIIa is NovoSeven® (Novo Nordisk A/S, Bagsvaerd, Denmark).
  • the invention relates to the use of factor VII or a factor Vll-related polypeptide in combination with a aprotinin for the manufacture of a medicament for enhancing fibrin clot formation in mammalian plasma.
  • the invention in another aspect, relates to a method of enhancing fibrin clot formation in a subject, which method comprises administering to a subject in need thereof a first amount of a preparation of factor VII or a factor Vll-related polypeptide and a second amount of a preparation of aprotinin or a aprotinin-related polypeptide, wherein the first and second amounts together are effective in treating bleedings.
  • FIGURES Figure 1 Addition of FVIIa (0-15 nM) results in a dose-dependent prolongation of the clot lysis time.
  • FIG. 2 In the presence of 10 nM FVIIa, addition of aprotinin resulted in a further prolongation of the clot lysis time. The effect was dose-dependent and optimal at 1 ⁇ M aprotinin.
  • moderate bleedings may lead to complications if they require the administration of human blood or blood products (platelets, leukocytes, plasma-derived concen- trates for the treatment of coagulation defects, etc.) because this is associated with the risk of transferring human viruses (e.g., hepatitis, HIV, parvovirus, or other, by now unknown viruses) as well as non-viral pathogens.
  • Extensive bleedings requiring massive blood transfusions may lead to the development of multiple organ failure including impaired lung and kidney function.
  • Subjects with thrombocytopenia also have an impaired thrombin generation as well as a defective stabilization of the fibrin plugs resulting in haemostatic plugs prone to premature dissolution.
  • subjects subjected to major trauma or organ damage and who, as a consequence, have obtained frequent blood transfusions often have lowered platelet counts as well as lowered levels of fibrinogen, factor VIII, and other coagulation proteins.
  • These subjects experience an impaired (or lowered) thrombin generation.
  • These subjects therefore, have a defective, or less efficient, haemostasis leading to the formation of fibrin plugs that are easily and prematurely dissolved by proteolytic enzymes, such enzymes in addition being extensively released in situations characterized by extensive trauma and organ damage.
  • haematomas Bleedings in tissues may also lead to the formation of haematomas.
  • the sizes of (in particular intercranial and spinal) haematomas are closely correlated to the extent of loss of neuro- logical function, rehabilitation difficulties, and/or the severity and degree of permanent impairments of neurological function following rehabilitation. The most severe consequences of haematomas are seen when they are located in the brain where they may even lead to the death of the patient.
  • the present invention thus provides beneficial compositions, uses and methods of treatment for treatment of bleeding episodes in subjects in need of such treatment.
  • the compositions, uses and methods may be associated with beneficial effects such as less blood loss before haemostasis is obtained, less blood needed during surgery, blood pressure kept at an acceptable level until haemostasis is obtained, faster stabilisation of blood pressure, shorter recovery time for the treated patient, shorter rehabilitation time for the treated patient, diminished formation of haematomas or formation of smaller haematomas, including haematomas in the brain, faster arrest of bleedings, reduction in the number of administrations needed to stop bleeding and maintain haemostasis.
  • a preparation of factor VII or a factor Vll-related polypeptide e.g., factor Vila
  • a preparation of aprotinin or a aprotinin-related polypeptide provides a shortened clotting time, a firmer clot and an increased resistance to f ibrinolysis compared to the clotting time, clot firmness and resistance when either factor Vila or aprotinin is administered alone.
  • the administration of a preparation of factor VII or a factor Vll-related polypeptide, e.g., factor Vila, in combination with a preparation of aprotinin or a aprotinin-related polypeptide also provides for a reduced time to obtain bleeding arrest and a reduced number of administrations to maintain haemostasis compared to the situation when either factor Vila or aprotinin is administered alone.
  • the present invention provides a beneficial effect of simultaneous or se- quential dosing of a preparation of aprotinin or an aprotinin-related polypeptide and a preparation of factor VII or a factor Vll-related polypeptide.
  • the pharmaceutical composition according to the present invention may be in the form of a single composition or it may be in the form of a multi-component kit (kit-of-parts).
  • kit-of-parts The composition according to the present invention is useful as a therapeutic and prophylactic procoagulant in mammals, including primates such as humans.
  • the present invention further provides a method for treating (including prophylactically treating or preventing) bleeding episodes in a subject, including a human being. Whenever, a first or second or third, etc., unit dose is mentioned throughout this specification this does not indicate the preferred order of administration, but is merely done for convenience purposes.
  • a combination of a preparation of factor VII or a factor Vll-related polypeptide and a preparation of aprotinin or a aprotinin-related polypeptide is an advantageous product ensuring short clotting times, rapid formation of haemostatic plugs, and formation of stable haemostatic plugs. It has been found by the present inventor that a combination of factor VII or a factor Vll- related polypeptide and a aprotinin or a aprotinin-related polypeptide is an advantageous product ensuring the formation of solid, stable and quickly formed haemostatic plugs.
  • the present inventors have shown that a combination of factor Vila and aprotinin can increase the firmness of the clot more effectively than either factor Vila or aprotinin alone. It has also been shown that combination of factor VII or a factor Vll-related polypeptide and a aprotinin can prolong the in vitro clot lysis time in normal human plasma more effectively than either factor Vila or aprotinin alone. It has also been shown that combination of factor VII or a factor Vll-related polypeptide and a aprotinin can prolong the half-clot lysis time in normal human plasma more effectively than either factor Vila or aprotinin alone.
  • factor VII or a factor Vll-related polypeptide and a aprotinin can protect the clot from fibrinolysis, in particular tPA-mediated fibrinolysis, in normal human plasma more effectively than either factor Vila or aprotinin alone.
  • tPA-mediated fibrinolysis in normal human plasma more effectively than either factor Vila or aprotinin alone.
  • the full thrombin generation is necessary for a solid, stabile haemostatic plug to be formed, and thereby for the maintenance of haemostasis.
  • the fibrin structure of such a plug is dependent on both the amount of thrombin formed and the rate of the initial thrombin generation.
  • a porous fibrin plug which is highly permeable, is being formed.
  • the fibrinolytic enzymes normally present on the fibrin surface easily dissolve such a fibrin plug.
  • the formation of a stable fibrin plug is also dependent on the presence of factor Xllla, which is being activated by thrombin and therefore also dependent on the full thrombin generation.
  • TAFl thrombin activatable fibrinolytic inhibitor
  • TAFl requires rather high thrombin amounts for its activation.
  • the TAFl may therefore not be activated resulting in the formation of a haemostatic plug, which is easier than normally dissolved by the normal fibrinolytic activity.
  • thrombocytopenia a faster thrombin generation is initiated by the administration of exogenous extra factor Vila.
  • the total thrombin generation is not normalised by factor Vila even in high concentrations.
  • Subjects with thrombocytopenia have an impaired thrombin generation as well as a defective stabilization of the fibrin plugs resulting in haemostatic plugs prone to premature disso- lution.
  • subjects subjected to major trauma or organ damage and who, as a consequence, have obtained frequent blood transfusions often have lowered platelet counts as well as lowered levels of fibrinogen, factor VIII, and other coagulation proteins.
  • These subjects experience an impaired (or lowered) thrombin generation.
  • their lowered fibrinogen level interfere negatively with the activation of factor XIII.
  • These subjects therefore, have a defective, or less efficient, haemostasis leading to the formation of fibrin plugs which are easily and prematurely dissolved by proteolytic enzymes, such enzymes in addition being extensively released in situations characterized by extensive trauma and organ damage.
  • compositions according to the invention are administered.
  • This composition is especially beneficial in subjects with a lowered number of platelets and in subjects with lowered plasma levels of fibrinogen and/or other coagulation proteins.
  • any factor VII polypeptide may be used that is effective in preventing or treating bleeding.
  • factor VII polypeptides such as, e.g., those having the amino acid sequence disclosed in U.S. Patent No. 4,784,950 (wild-type human factor VII).
  • the factor VII polypeptide is human factor Vila, as disclosed, e.g., in U.S. Patent No. 4,784,950 (wild-type factor VII).
  • factor VII polypeptides include polypeptides that exhibit at least about 10%, preferably at least about 30%, more preferably at least about 50%, and most preferably at least about 70%, of the specific biological activity of human factor Vila.
  • factor VII polypeptides include polypeptides that exhibit at least about 90%, preferably at least about 100%, preferably at least about 120%, more preferably at least about 140%, and most preferably at least about 160%, of the specific biological activity of human factor Vila.
  • factor VII polypeptides include polypeptides that exhibit at least about 70 %, preferably at least about 80 %, more preferably at least about 90 %, and most preferable at least about 95 %, of identity with the sequence of wild-type factor VII as disclosed in U.S. Patent No. 4,784,950.
  • factor VII polypeptide encompasses, without limitation, factor VII, as well as factor Vll-related polypeptides.
  • factor VII is intended to encompass, without limitation, polypeptides having the amino acid sequence 1-406 of wild-type human factor VII (as disclosed in U.S. Patent No. 4,784,950), as well as wild-type factor VII derived from other species, such as, e.g., bovine, porcine, canine, murine, and salmon factor VII, said factor VII derived from blood or plasma, or produced by recombinant means. It further encompasses natural allelic variations of factor VII that may exist and occur from one individual to another. Also, degree and location of glycosylation or other post-translation modifications may vary depending on the chosen host cells and the nature of the host cellular environment.
  • factor VII is also intended to encompass factor VII polypeptides in their uncleaved (zymogen) form, as well as those that have been proteolytically processed to yield their respective bioactive forms, which may be designated factor Vila. Typically, factor VII is cleaved between residues 152 and 153 to yield factor Vila.
  • Factor Vll-related polypeptides include, without limitation, factor VII polypeptides that have either been chemically modified relative to human factor VII and/or contain one or more amino acid sequence alterations relative to human factor VII (i.e., factor VII variants), and/or contain truncated amino acid sequences relative to human factor VII (i.e., factor VII fragments). Such factor Vll-related polypeptides may exhibit different properties relative to human factor VII, including stability, phospholipid binding, altered specific activity, and the like.
  • factor Vll-related polypeptides are intended to encompass such polypeptides in their uncleaved (zymogen) form, as well as those that have been proteolytically processed to yield their respective bioactive forms, which may be designated "factor Vila-related polypeptides" or "activated factor Vll-related polypeptides"
  • factor Vll-related polypeptides encompasses, without limitation, polypeptides exhibiting substantially the same or improved biological activity relative to wild- type human factor VII, as well as polypeptides in which the factor Vila biological activity has been substantially modified or reduced relative to the activity of wild-type human factor Vila.
  • polypeptides include, without limitation, factor VII or factor Vila that has been chemically modified and factor VII variants into which specific amino acid sequence alterations have been introduced that modify or disrupt the bioactivity of the polypeptide.
  • polypeptides with a slightly modified amino acid sequence for instance, polypeptides having a modified N-terminal end including N-terminal amino acid deletions or additions, and/or polypeptides that have been chemically modified relative to human factor Vila.
  • Factor Vll-related polypeptides including variants of factor VII, whether exhibiting substantially the same or better bioactivity than wild-type factor VII, or, alternatively, exhibiting substantially modified or reduced bioactivity relative to wild-type factor VII, include, without limitation, polypeptides having an amino acid sequence that differs from the sequence of wild- type factor VII by insertion, deletion, or substitution of one or more amino acids.
  • Factor Vll-related polypeptides encompass those that exhibit at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, at least about 100%, at least about 1 10%, at least about 120%, or at least about 130%, of the specific activity of wild-type factor Vila that has been produced in the same cell type, when tested in one or more of a clotting assay, proteolysis assay, or TF binding assay as described above.
  • Factor Vll-related polypeptides having substantially the same or improved biological activity relative to wild-type factor Vila encompass those that exhibit at least about 25%, preferably at least about 50%, more preferably at least about 75%, more preferably at least about 100%, more preferably at least about 110%, more preferably at least about 120%, and most preferably at least about 130% of the specific activity of wild-type factor Vila that has been produced in the same cell type, when tested in one or more of a clotting assay, proteolysis assay, or TF binding assay as described above.
  • Factor Vll-related polypeptides including variants, having substantially reduced biological activity relative to wild-type factor Vila are those that exhibit less than about 25%, preferably less than about 10%, more preferably less than about 5% and most preferably less than about 1 % of the specific activity of wild-type factor Vila that has been produced in the same cell type when tested in one or more of a clotting assay, proteolysis assay, or TF binding assay as described above, factor VII variants having a substantially modified biological activity relative to wild-type factor VII include, without limitation, factor VII variants that exhibit TF- independent factor X proteolytic activity and those that bind TF but do not cleave factor X.
  • the factor VII polypeptides are factor Vll-related polypeptides, in particular variants, wherein the ratio between the activity of said factor VII polypeptide and the activity of native human factor Vila (wild-type FVIIa) is at least about 1.25 when tested in the " In Vitro Hydrolysis Assay” (see “Assays", below); in other embodiments, the ratio is at least about 2.0; in further embodiments, the ratio is at least about 4.0.
  • the factor VII polypeptides are factor Vll-related polypeptides, in particular variants, wherein the ratio between the activity of said factor VII polypeptide and the activity of native human factor Vila (wild-type FVIIa) is at least about 1.25 when tested in the "In Vitro Proteolysis Assay” (see “Assays", below); in other embodiments, the ratio is at least about 2.0; in further embodiments, the ratio is at least about 4.0; in further embodiments, the ratio is at least about 8.0.
  • the factor VII polypeptide is human factor VII, as disclosed, e.g., in U.S. Patent No. 4,784,950 (wild-type factor VII).
  • the factor VII polypeptide is human factor Vila.
  • the factor VII polypeptides are factor Vll-related polypeptides that exhibits at least about 10%, preferably at least about 30%, more preferably at least about 50%, and most preferably at least about 70%, of the specific biological activity of human factor Vila.
  • the factor VII polypeptides have an amino acid sequence that differs from the sequence of wild-type factor VII by insertion, deletion, or substitution of one or more amino acids.
  • Non-limiting examples of factor VII variants having substantially the same or better biological activity compared to wild-type factor Vila include, but are not limited to, those described in Danish Patent Applications Nos. PA 2000 00734 and PA 2000 01360 (corresponding to WO 01/83725), and PA 2000 01361 (corresponding to WO 02/22776).
  • Non-limiting examples of factor VII variants having substantially the same or improved biological activity as wild-type factor VII include S52A-FVII, S60A-FVII (lino et al., Arch. Biochem. Biophys.
  • Patent No. 5,580,560 factor Vila that has been proteolytically cleaved between residues 290 and 291 or between residues 315 and 316 (Mollerup et al., Biotechnol. Bioeng. 48:501-505, 1995); and oxidized forms of factor Vila (Komfelt et al., Arch. Biochem. Biophys. 363:43-54, 1999).
  • Non-limiting examples of factor VII variants having substantially reduced or modified biological activity relative to wild-type factor VII include R152E-FVIIa (Wildgoose et al., Biochem 29:3413-3420, 1990), S344A-FVIIa (Kazama et al., J. Biol. Chem.
  • factor Vila in blood clotting derives from its ability to (i) bind to tissue factor (TF) and (ii) catalyze the proteolytic cleavage of factor IX or factor X to produce activated factor IX or X (factor IXa or Xa, respectively).
  • factor VII biological activity may be quantified by measuring the ability of a preparation to promote blood clotting using factor Vll-deficient plasma and thromboplastin, as described, e.g., in U.S. Patent No. 5,997,864.
  • biological activity is expressed as the reduction in clotting time relative to a control sample and is converted to "factor VII units” by comparison with a pooled human serum standard containing 1 unit/ml factor VII activity.
  • factor Vila biological activity may be quantified by (i) Measuring the ability of factor Vila or a factor Vila -related polypeptide to produce activated factor X (factor Xa) in a system comprising TF embedded in a lipid membrane and factor X. (Persson et al., J. Biol. Chem. 272:19919-19924, 1997);
  • factor VII biological activity or "factor VII activity” is intended to include the ability to generate thrombin; the term also includes the ability to generate thrombin on the surface of activated platelets in the absence of tissue factor.
  • a factor Vila preparation that may be used according to the invention is, without limitation, NovoSeven® (Novo Nordisk A/S, Bagsvaerd, Denmark).
  • aprotinin polypeptides such as, e.g., those having the amino acid sequence of wild-type bovine aprotinin as well as aprotinin analogs, e.g those disclosed in Castro MJ. et al. Biochemistry 1996 Sep 3;35(35):11435-46; Stassen et al., Thromb Haemost. 1995 Aug;74(2):655-9; Stassen et al. hromb Haemost. 1995 Aug;74(2):646-54; Grzesiak A. et al. J Mol Biol 2000 Aug 4;301(1):205-17; WO 89/10374, US Patent No.
  • any aprotinin polypeptide may be used that is effective in preventing or treating bleeding. This includes aprotinin polypeptides derived from bovine tissue, or produced by recombinant means.
  • aprotinin polypeptide encompasses, without limitation, aprotinin, as well as aprotinin-related polypeptides.
  • the term “aprotinin” is intended to encompass, without limitation, polypeptides having the amino acid sequence of native bovine aprotinin (wild-type bovine aprotinin), as well as wild-type aprotinin derived from other species, such as, e.g., porcine, canine, murine, and salmon aprotinin.
  • porcine canine, murine, and salmon aprotinin.
  • the term “aprotinin” is intended to encompass all naturally occuring aprotinin polypeptides.
  • aprotinin is also intended to encompass, without limitation, polypeptides having the amino acid sequence of wild-type aprotinin, as well as wild-type aprotinin derived from other species, such as, e.g., porcine, canine, or murine aprotinin. It further encompasses natural allelic variations of aprotinin that may exist and occur from one individual to another. Also, degree and location of glycosylation or other post-translation modifications may vary depending on the chosen host cells and the nature of the host cellular environment.
  • aprotinin is also intended to encompass aprotinin polypeptides in their zymogen form, as well as those that have been processed to yield their respective bioactive forms.
  • Aprotinin-related polypeptides include, without limitation, aprotinin polypeptides that have either been chemically modified relative to bovine aprotinin and/or contain one or more amino acid sequence alterations relative to bovine aprotinin (i.e., aprotinin variants), and/or contain truncated amino acid sequences relative to bovine aprotinin (i.e., aprotinin fragments) and/or Kunitz-type inhibitor polypeptides with aprotinin activity.
  • Such aprotinin- related polypeptides may exhibit different properties relative to bovine aprotinin, including stability, phospholipid binding, altered specific activity, and the like.
  • aprotinin-related polypeptides are intended to encompass such polypeptides in their zymogen form, as well as those that have been processed to yield their respective bioactive forms.
  • aprotinin-related polypeptides encompasses, without limitation, polypeptides exhibiting substantially the same or improved biological activity relative to wild- type bovine aprotinin, as well as polypeptides, in which the aprotinin biological activity has been substantially modified or reduced relative to the activity of wild-type bovine aprotinin.
  • These polypeptides include, without limitation, aprotinin that has been chemically modified and aprotinin variants into which specific amino acid sequence alterations have been introduced that modify or disrupt the bioactivity of the polypeptide.
  • polypeptides with a slightly modified amino acid sequence for instance, polypeptides having a modified N-terminal end including N-terminal amino acid deletions or additions, and/or polypeptides that have been chemically modified relative to bovine aprotinin.
  • Aprotinin-related polypeptides include, without limitation, polypeptides having an amino acid sequence that differs from the sequence of wild- type aprotinin by insertion, deletion, or substitution of one or more amino acids.
  • Aprotinin-related polypeptides encompass those that exhibit at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 110%, at least about 120%, and at least about 130%, of the specific activity of wild-type aprotinin that has been produced in the same cell type, when tested in the aprotinin activity assay as described in the present specification.
  • Aprotinin-related polypeptides including variants, having substantially the same or improved biological activity relative to wild-type aprotinin encompass those that exhibit at least about 25%, preferably at least about 50%, more preferably at least about 75%, more preferably at least about 100%, more preferably at least about 110%, more preferably at least about 120%, and most preferably at least about 130% of the specific biological activity of wild-type bovine aprotinin that has been produced in the same cell type when tested in one or more of the specific aprotinin activity assay as described.
  • aprotinin biological activity may be quantified, for example, as described by Cardigan et al., Blood Coagulation & Fibrinolysis 2001; 12:37-42 (se "assay part" of the present description).
  • Aprotinin-related polypeptides, including variants, having substantially reduced biological activity relative to wild-type aprotinin are those that exhibit less than about 25%, preferably less than about 10%, more preferably less than about 5% and most preferably less than about 1 % of the specific activity of wild-type aprotinin that has been produced in the same cell type when tested in one or more of the specific aprotinin activity assays as described above.
  • Non-limiting examples of equivalents include aprotinin equivalents described in e.g. WO 89/10374 US Patent No. 5591603, US Patent No. 5618915, US Patent No. 5621074, European Patent No. 375718, European Patent No. 339942, US Patent No.
  • the aprotinin polypeptide are aprotinin equivalents wherein the ratio between the activity of said aprotinin polypeptide and the activity of native bovine aprotinin (wild-type aprotinin) is at least about 1.25 when tested in an aprotinin activity assay; in other embodiments, the ratio is at least about 2.0; in further embodiments, the ratio is at least about 4.0.
  • the aprotinin polypeptide are aprotinin equivalents wherein the ratio between the activity of said aprotinin polypeptide and the activity of native bovine aprotinin (wild-type aprotinin) is at least about 1.25 when tested in the "aprotinin assay"; in other embodiments, the ratio is at least about 2.0; in further embodiments, the ratio is at least about 4.0.
  • Aprotinin-related polypeptides also include fragments of aprotinin or aprotinin-related polypeptides retaining their characteristic haemostasis-related activity. The haemostasis-related activity of a aprotinin polypeptide may, for example, be measured using the aprotinin-activity assay described in the present specification.
  • amino acids mentioned herein are L-amino acids. It is to be understood, that the first letter in, for example, K337 represent the amino acid naturally present at the indicated position wild-type factor VII, and that, for example, [K337A]-FVIIa designates the FVII-variant wherein the amino acid represented by the one-letter code K naturally present in the indicated position is replaced by the amino acid represented by the one-letter code A.
  • Table 1 Abbreviations for amino acids:
  • factor Vila or "FVIIa” may be used interchangeably.
  • "subjects with an impaired thrombin generation” means subjects who cannot generate a full thrombin burst on the activated platelet surface and includes subjects having a generation of thrombin less that the thrombin-generation in subjects having a fully functioning, normal haemostatic system, including a normal amount and function of coagulation factors, platelets and fibrinogen (e.g., as in pooled, normal human plasma), and includes, without limitations, subjects lacking factor VIII; subjects having a lowered number of platelets or platelets with a defective function (e.g., thrombocytopenia or thrombasthenia Glanzmann or subjects with excessive bleeds); subjects having lowered levels of prothrombin, FX or FVII; subjects having a lowered level of several coagulation factors (e.g., due to exessive bleeding as a consequence of trauma or extensive surgery); and subjects with lowered plasma concentrations of fibr
  • level of thrombin generation or "normal thrombin generation” is meant the level of the patient's level of thrombin generation compared to the level in healthy subjects. The level is designated as a percentage of the normal level. The terms may, where appropriate, be used interchangeably.
  • the term "enhancement of the haemostatic system” means an enhancement of the ability to generate thrombin.
  • the term “enhancing haemostasis” is intended to encompass the situations when the measured thrombin generation for a test sample containing a preparation of factor VII or a factor Vll-related polypeptide and a preparation of aprotinin or a aprotinin-related polypeptide is prolonged relative to the individual thrombin generation of a control sample containing only the factor VII or factor Vll-related polypeptide or the aprotinin or aprotinin-related polypeptide, respectively, when tested in the same thrombin generation assay.
  • the thrombin generation may be assayed as described in the thrombin generation assay of the present description (see “assay part”).
  • “Sole” agents or factors as used herein refers to situations in which the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide, taken together, are the only haemostatic agents, or active haemostatic agents, or coagulation factors contained in the pharmaceutical composition or kit, or are the only haemostatic agents,or active haemo- static agents, or coagulation factors administered to the patient in the course of a particular treatment, such as, e.g., in the course of a particular bleeding episode.
  • Clot lysis time, clot strength, fibrin clot formation, and clotting time are clinical parameters used for assaying the status of patient's haemostatic system. Blood samples are drawn from the patient at suitable intervals and one or more of the parameters are assayed by means of, e.g., thromboelastograpy as described by, e.g., Meh et al.,Blood Coagulation & Fibrinolysis 2001;12:627- 637; Vig et al., Hematology, Vol.
  • the term "prolonging clot lysis time" is intended to encompass the situations when the measured clot lysis time for a test sample containing a preparation of factor VII or a factor VII- related polypeptide and a preparation of aprotinin or a aprotinin-related polypeptide is prolonged relative to the individual clot lysis time of a control sample containing only the factor VII or factor Vll-related polypeptide or the aprotinin or aprotinin-related polypeptide, respectively, when tested in the same clot lysis assay.
  • the clot lysis time may be assayed as described above.
  • the term "increasing clot strength" is intended to encompass the situations when the measured clot strength, e.g., mechanical strength, for a test sample containing a preparation of factor VII or a factor Vll-related polypeptide and a preparation of aprotinin or a aprotinin-related polypeptide is increased relative to the individual clot lysis time of a control sample containing only the factor VII or factor Vll-related polypeptide or the aprotinin or aprotinin-related polypeptide, respectively, when tested in the same clot strength assay.
  • the clot strength may be assayed as described, e.g. in Carr et al, 1991. (Carr ME, Zekert SL. Measurement of platelet-mediated force development during plasma clot formation. AM J MED SCI 1991; 302: 13-8), or as described above by means of thromboelastography.
  • enhancing fibrin clot formation is intended to encompass the situations when the measured rate for or degree of fibrin clot formation for a test sample containing a preparation of factor VII or a factor Vll-related polypeptide and a preparation of a preparation of aprotinin or a aprotinin-related polypeptide is increased relative to the individual rate for or degree of fibrin clot formation of a control sample containing only the factor VII or factor Vll-related polypeptide or the aprotinin or aprotinin-related polypeptide, respectively, when tested in the same clotting assay.
  • the fibrin clot formation may be assayed as described above.
  • shortening clotting time is intended to encompass the situations when the measured time for clot formation (clotting time) for a test sample containing a preparation of factor VII or a factor Vll-related polypeptide and a preparation of a preparation of aprotinin or a aprotinin-related polypeptide is increased relative to the individual clotting time of a control sample containing only the factor VII or factor Vll-related polypeptide or the aprotinin or aprotinin-related polypeptide respectively, when tested in the same clotting assay.
  • the clotting time may be assayed by means of standard PT og aPTT assays, which are known to the general skilled person.
  • lowered count or activity of platelets refers to the number of platelets (throm- bocytes) present in the subject's plasma and to the biological, coagulation-related activity of such platelets. Lowered counts may be due, e.g., to increased platelet destruction, decreased platelet production, and pooling of a larger than normal fraction of platelets in the spleen.
  • Thrombocyto- penia for example, is defined as a platelet count less than 150,000 platelets per microliter; the upper limit of the normal platelet count is generally considered to be between 350,000 and 450,000 platelets per microliter. Platelet count may be measured by automated platelet counters; this is a well known method to the skilled worker.
  • Syndromes due to lowered platelet count include, without limitation, thrombocytopenia, coagulophathy.
  • Activity includes, without limitation, aggrega- tion, adhesion, and coagulant activity of the platelets. Decreased activity may be due, e.g., to glyco- protein abnormalities, abnormal membrane-cytoskeleton interaction, abnormalities of platelet granules, abnormalities of platelet coagulant activity, abnormalities of signal transduction and se- cretion. Platelet activity, including aggregation, adhesion, and coagulant activity, are measured by standard methods known to the skilled worker, see e.g.,Platelets. A Practical Approach, Ed. S.P. Watson & K.S.
  • bleeding disorder reflects any defect, congenital, acquired or in- prised, of cellular or molecular origin that is manifested in bleeding episodes.
  • bleeding disorders include, but are not limited to, clotting factor deficiencies (e.g.
  • coagulation factors VIII, IX, XI or VII deficiency of coagulation factors VIII, IX, XI or VII
  • clotting factor inhibitors e.g., Glanzmann thombasthenia and Bernard-Soulier syndrome
  • thrombocytopenia e.g., von Willebrand's disease
  • coagulophathy e.g., a dilution of coagulation proteins, increased fibrinolysis and lowered number of platelets due to bleedings and/or transfusions (e.g., in multi transfused subjects having been subjected to surgery or trauma).
  • Bleeding refers to extravasation of blood from any component of the circulatory system.
  • the term "bleeding episodes” is meant to include unwanted, uncontrolled and often excessive bleeding in connection with surgery, trauma, or other forms of tissue damage, as well as un- wanted bleedings in subjects having bleeding disorders. Bleeding episodes may occur in subjects having a basically normal coagulation system but experiencing a (temporary) coagulophathy, as well as in subjects having congenital or acquired coagulation or bleeding disorders.
  • the bleedings may be likened to bleedings caused by haemophilia because the haemostatic system, as in haemophilia, lacks or has abnormal essential clotting "compounds" (e.g., platelets or von Willebrand factor protein).
  • compounds e.g., platelets or von Willebrand factor protein.
  • the normal haemostatic mechanism may be overwhelmed by the demand of immediate haemostasis and they may develop excessive bleeding in spite of a basically (pre-trauma or pre-surgery) normal haemostatic mechanism.
  • Such subjects who further often are multi transfused, develop a (tem- porary) coagulopathy as a result of the bleeding and/or transfusions (i.e., a dilution of coagulation proteins, increased fibrinolysis and lowered number of platelets due to the bleeding and/or transfusions).
  • Bleedings may also occur in organs such as the brain, inner ear region and eyes; these are areas with limited possibilities for surgical haemostasis and thus problems with achieving satisfactory haemostasis. Similar problems may arise in the process of taking biopsies from various organs (liver, lung, tumour tissue, gastrointestinal tract) as well as in laparoscopic surgery and radical retropubic prostatectomy.
  • Such therapy may include heparin, other forms of pro- teoglycans, warfarin or other forms of vitamin K-antagonists as well as aspirin and other platelet aggregation inhibitors, such as, e.g., antibodies or other inhibitors of GP llb/llla activity.
  • the bleeding may also be due to so-called thrombolytic therapy which comprises combined treatment with an antiplatelet agent (e.g., acetylsalicylic acid), an anticoagulant (e.g., heparin), and a fibrinolytic agent (e.g., tissue plasminogen activator, tPA).
  • an antiplatelet agent e.g., acetylsalicylic acid
  • an anticoagulant e.g., heparin
  • a fibrinolytic agent e.g., tissue plasminogen activator, tPA
  • Bleeding episodes are also meant to include, without limitation, uncontrolled and excessive bleeding in connection with surgery or trauma in subjects having acute haemarthroses (bleedings in joints), chronic haemophilic ar- thropathy, haematomas, (e.g., muscular, retroperitoneal, sublingual and retropharyngeal), bleedings in other tissue, haematuria (bleeding from the renal tract), cerebral haemorrhage, surgery (e.g., hepatectomy), dental extraction, and gastrointestinal bleedings (e.g., UGI bleeds).
  • acute haemarthroses bleedings in joints
  • chronic haemophilic ar- thropathy e.g., ar- thropathy
  • haematomas e.g., muscular, retroperitoneal, sublingual and retropharyngeal
  • bleedings in other tissue e.g., haematuria (bleeding from the renal tract), cerebral haemorrhage, surgery (e.g., hepat
  • the bleeding episodes may be associated with inhibitors against factor VIII; haemophilia A; haemophilia A with inhibitors; haemophilia B; deficiency of factor VII; deficiency of aprotinin; thrombocytopenia; deficiency of von Willebrand factor (von Willebrand's disease); severe tissue damage; severe trauma; surgery; laparoscopic surgery; haemorrhagic gastritis; taking biopsies; anticoagulant therapy; upper gastroentestinal bleedings (UGI); or stem cell transplantation.
  • the bleeding episodes may be profuse uterine bleeding; occurring in organs with a limited possibility for mechanical haemostasis; occurring in the brain; occurring in the inner ear region; or occurring in the eyes.
  • the terms “bleeding episodes” and “bleedings” may, where appropriate, be used interchangeably.
  • treatment is meant to include both prevention of an ex- pected bleeding, such as, for example, in surgery, and regulation of an already occurring bleeding, such as, for example, in trauma, with the purpose of inhibiting or minimising the bleeding.
  • expected bleeding may be a bleeding expected to occur in a particular tissue or organ, or it may be an unspecified bleeding.
  • Prophylactic administration of a preparation of factor VII or a factor Vll-related polypeptide and a preparation of aprotinin or a aprotinin-related polypeptide is thus included in the term "treatment".
  • the term "subject” as used herein is intended to mean any animal, in particular mammals, such as humans, and may, where appropriate, be used interchangeably with the term “patient”.
  • the present invention also encompasses the use of factor VII or FVII-related polypeptides, and tPA inhibitors within veterinary procedures.
  • the factor VII or factor Vll-related polypeptides and aprotinin or aprotinin-related polypeptides as defined in the present specification may be administered simultaneously or sequentially.
  • the factors may be supplied in single-dosage form wherein the single-dosage form contains both coagulation factors, or in the form of a kit-of-parts comprising a preparation of factor VII or a factor Vll-related polypeptide as a first unit dosage form and a preparation of aprotinin or a aprotinin-related polypeptide as a second unit dosage form.
  • a first or second or third, etc., unit dose is mentioned throughout this specification this does not indicate the preferred order of administration, but is merely done for convenience purposes
  • a preparation of factor VII or a factor Vll-related polypeptide and a preparation of aprotinin or a aprotinin-related polypeptide is meant administration of the coagulation factor proteins in single-dosage form, or administration of a first coagulation factor protein followed by administration of a second coagulation factor protein with a time separation of no more than 15 minutes, preferably 10, more preferred 5, more preferred 2 minutes. Either factor may be administered first.
  • sequential dosing administration of a first coagulation factor protein followed by administration of a second coagulation factor protein with a time separation of up to 2 hours, preferably from 1 to 2 hours, more preferred up to 1 hour, more preferred from 30 minutes to 1 hour, more preferred up to 30 minutes, more preferred from 15 to 30 minutes.
  • Either of the two unit dosage form, or coagulation factor proteins may be administered first.
  • both products are injected through the same intravenous access.
  • One unit of factor VII is defined as the amount of factor VII present in 1 ml of normal plasma, corresponding to about 0.5 ⁇ g protein. After activation 50 units correspond to about 1 ⁇ g protein.
  • defect is meant a decrease in the presence or activity of, e.g., factor VII in plasma compared to that of normal healthy individuals.
  • the term may, where appropriate, be used interchangeably with “reduced factor VII level”.
  • APTT or "aPTT” is meant the activated partial thromboplastin time (described by, e.g., Proctor RR, Rapaport SI: The partial thromboplastin time with kaolin; a simple screening test for first-stage plasma clotting factor deficiencies. Am J Clin Pathol 36:212, 1961).
  • aprotinin-responsive syndrome is meant a syndrome where exogenous aprotinin administered to the subject in need thereof may prevent, cure or ameliorate any symptoms, conditions or diseases, expected or present, caused by the syndrome.
  • a aprotinin-responsive syn- drome may also be treated with a composition according to the present invention.
  • factor Vll-responsive syndrome is meant a syndrome where exogenous factor VII, preferably factor Vila, administered to the subject in need thereof may prevent, cure or ameliorate any symptoms, conditions or diseases, expected or present, caused by the syndrome. Included are, without limitation, syndromes caused by a reduced level of clotting factors VIII, IX, XI or VII, clotting factor inhibitors, defective platelet function (e.g., Glanzmann thombasthenia and Bernard-Soulier syndrome), thrombocytopenia, von Willebrand's disease, and coagulophathy such as that caused by a dilution of coagulation proteins, increased fibrinolysis and lowered number of platelets due to bleedings and/or transfusions (e.g., in multi transfused subjects having been subjected to surgery or trauma).
  • clotting factors VIII, IX, XI or VII clotting factor inhibitors
  • defective platelet function e.g., Glanzmann thombasthenia and Bernard-Soul
  • Half-life refers to the time required for the plasma concentration of factor VII or a factor Vll-related polypeptide, or aprotinin or a aprotinin-related polypeptide to decrease from a particular value to half of that value.
  • primary haemostasis is meant the initial generation of thrombin by FXa and TF:factor Vila, the subsequent activation of platelets and formation of the initial loose plug of activated, adhered platelets which has not yet been stabilized by fibrin and, finally, by cross- linked fibrin. If not stabilized by the fibrin formed during the second step of the haemostatic process (maintained haemostasis), the plug is easily dissolved by the fibrinolytic system.
  • second haemostasis or “maintained haemostasis” is meant the secondary, full, and major, burst or generation of thrombin taking place on the surface of activated platelets and catalysed by factor Villa and factor Villa, the subsequent formation of fibrin and the stabilization of the initial platelet plug. Stabilization of the plug by fibrin leads to full haemostasis.
  • full haemostasis is meant the formation of a stable and solid fibrin clot or plug at the site of injury which effectively stops the bleeding and which is not readily dissolved by the fibrinolytic system.
  • haemostasis will be used to represent full haemostasis as described above.
  • the total amount of protein in a preparation may be measured by generally known methods, e.g, by measuring optical density.
  • Amounts of aprotinin- or factor VII protein ("antigen") may be measured by generally known methods such as standard Elisa immuno assays. In general terms, such assay is conducted by contacting, e.g., a solution of the aprotinin protein- containing preparation with an anti-thromobomodulin antibody immobilised onto the elisa plate, subsequently contacting the immobilised antibody-aprotinin complex with a second anti- aprotinin antibody carrying a marker, the amounts of which, in a third step, are measured.
  • the amounts of each coagulation factor may be measured in a similar way using appropriate antibodies.
  • the total amount of coagulation factor protein present in a preparation is determined by adding the amounts of the individual coagulation factor proteins.
  • the preparation comprises isolated coagulation factor.
  • the preparation is essentially free of coagulation factor II and coagulation factor lla (prothrombin and thrombin) and/or factor X or Xa.
  • isolated refers to coagulation factors, e.g., aprotinin or aprotinin-related polypeptides that have been separated from the cell in which they were synthesized or the medium in which they are found in nature (e.g., plasma or blood). Separation of polypeptides from their cell of origin may be achieved by any method known in the art, including, without limitation, removal of cell culture medium containing the desired product from an adherent cell culture; centrifugation or filtration to remove non-adherent cells; and the like.
  • Separation of polypeptides from the medium in which they naturally occur may be achieved by any method known in the art, including, without limitation, affinity chromatography, such as, e.g., on an anti-factor VII or anti-aprotinin antibody column, respectively; hydrophobic interaction chromatography; ion-exchange chromatography; size exclusion chromatography; electro- phoretic procedures (e.g., preparative isoelectric focusing (IEF)), differential solubility (e.g., ammonium sulfate precipitation), or extraction and the like.
  • affinity chromatography such as, e.g., on an anti-factor VII or anti-aprotinin antibody column, respectively
  • hydrophobic interaction chromatography e.g., ion-exchange chromatography
  • size exclusion chromatography e.g., electro- phoretic procedures (e.g., preparative isoelectric focusing (IEF)), differential solubility (e.g., ammonium sulfate
  • an "effective amount" of factor VII or a factor Vll-related polypeptide, and aprotinin or a aprotinin-related polypeptide is defined as the amount of factor VII or a factor Vll-related polypeptide, e.g., FVIIa, and aprotinin or a aprotinin-related polypep- tide, that together suffices to prevent or reduce bleeding or blood loss, so as to cure, alleviate or partially arrest the disease and its complications.
  • activity of factor Vila or "factor Vila-activity” includes the ability to generate thrombin; the term also includes the ability to generate thrombin on the surface of activated platelets in the absence of tissue factor.
  • Human purified factor Vila suitable for use in the present invention is preferably made by DNA recombinant technology, e.g. as described by Hagen et al., Proc.Natl.Acad.Sci. USA 83: 2412- 2416, 1986, or as described in European Patent No. 200.421 (ZymoGenetics, Inc.).
  • Factor VII may also be produced by the methods described by Broze and Majerus, J.Biol.Chem. 255 (4): 1242-1247, 1980 and Hedner and Kisiel, J.Clin.lnvest. 71: 1836-1841, 1983. These methods yield factor VII without detectable amounts of other blood coagulation factors.
  • An even further purified factor VII preparation may be obtained by including an additional gel filtration as the final purification step, factor VII is then converted into activated factor Vila by known means, e.g. by several different plasma proteins, such as aprotininla, IX a or Xa.
  • factor VII may be activated by passing it through an ion-exchange chromatography column, such as Mono Q® (Pharmacia fine Chemicals) or the like.
  • Factor VII -related polypeptides may produced by modification of wild-type factor VII or by recombinant technology, factor VII -related polypeptides with altered amino acid sequence when compared to wild-type factor VII may be produced by modifying the nucleic acid sequence encoding wild-type factor VII either by altering the amino acid codons or by removal of some of the amino acid codons in the nucleic acid encoding the natural factor VII by known means, e.g. by site-specific mutagenesis. It will be apparent to those skilled in the art that substitutions can be made outside the regions critical to the function of the factor Vila or aprotinin-molecule and still result in an active polypeptide.
  • Amino acid residues essential to the activity of the factor VII or factor Vll-related polypeptide or aprotinin or aprotinin-related polypeptide, and therefore preferably not subject to substitution may be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (see, e.g., Cunningham and Wells, 1989, Science 244: 1081-1085). In the latter technique, mutations are introduced at every positively charged residue in the molecule, and the resultant mutant molecules are tested for coagulant, respectively cross-linking activity to identify amino acid residues that are critical to the activity of the molecule.
  • Sites of substrate-enzyme interaction can also be determined by analysis of the three- dimensional structure as determined by such techniques as nuclear magnetic resonance analysis, crystallography or photoaffinity labelling (see, e.g., de Vos et al., 1992, Science 255: 306-312; Smith et al., 1992, Journal of Molecular Biology 224: 899-904; Wlodaver et al., 1992, FEBS Letters 309: 59-64).
  • the introduction of a mutation into the nucleic acid sequence to exchange one nucleo- tide for another nucleotide may be accomplished by site-directed mutagenesis using any of the methods known in the art. Particularly useful is the procedure that utilizes a super coiled, double stranded DNA vector with an insert of interest and two synthetic primers containing the desired mutation.
  • the oligonucleotide primers, each complementary to opposite strands of the vector, extend during temperature cycling by means of Pfu DNA polymerase. On incorporation of the primers, a mutated plasmid containing staggered nicks is generated.
  • Dpnl is specific for methylated and hemi- methylated DNA to digest the parental DNA template and to select for mutation-containing synthesized DNA.
  • Other procedures known in the art for creating, identifying and isolating variants may also be used, such as, for example, gene shuffling or phage display techniques. Separation of polypeptides from their cell of origin may be achieved by any method known in the art, including, without limitation, removal of cell culture medium containing the desired product from an adherent cell culture; centrifugation or filtration to remove non- adherent cells; and the like.
  • factor VII or factor Vll-related polypeptides may be further purified.
  • Purifi- cation may be achieved using any method known in the art, including, without limitation, affinity chromatography, such as, e.g., on an anti-factor VII antibody column (see, e.g., Wakabayashi et al., J. Biol. Chem. 261:11097, 1986; and Thim et al., Biochem.
  • the preparation preferably contains less than about 10% by weight, more preferably less than about 5% and most preferably less than about 1 %, of non-factor VII or factor Vll-related polypeptides derived from the host cell.
  • Factor VII or factor Vll-related polypeptides may be activated by proteolytic cleavage, using f ⁇ ctor Xla or other proteases having trypsin-like specificity, such as, e.g., factor IXa, kallik- rein, factor Xa, and thrombin.
  • proteolytic cleavage using f ⁇ ctor Xla or other proteases having trypsin-like specificity, such as, e.g., factor IXa, kallik- rein, factor Xa, and thrombin.
  • factor VII or factor Vll-related polypeptides may be activated by passing it through an ion-exchange chromatography column, such as Mono Q® (Pharmacia) or the like.
  • the resulting activated factor VII or factor Vll-related polypeptide may then be formulated and administered as described below.
  • Aprotinin for use within the present invention may be isolated as already mentioned. It is preferred, however, to use recombinant aprotinin so as to avoid to the use of blood- or tissue- derived products that carry a risk of disease transmission. Methods for preparing recombinant aprotinin are known in the art. Aprotinin variants may be produced by means of site-directed mutagenesis as described above.
  • Aprotinin -related polypeptides may produced by modification of wild-type aprotinin or by recombinant technology, aprotinin -related polypeptides with altered amino acid sequence when compared to wild-type aprotinin may be produced by modifying the nucleic acid sequence encoding wild-type aprotinin either by altering the amino acid codons or by removal of some of the amino acid codons in the nucleic acid encoding the natural aprotinin by known means, e.g. by site-specific mutagenesis, as described in more detail above.
  • Separation of polypeptides from their cell of origin may be achieved by any method known in the art, including, without limitation, removal of cell culture medium containing the desired product from an adherent cell culture; centrifugation or filtration to remove non-adherent cells; and the like.
  • aprotinin or aprotinin- related polypeptides may be further purified.
  • Purification may be achieved using any method known in the art, including, without limitation, affinity chromatography, such as, e.g., on an anti-aprotinin antibody column; hydrophobic interaction chromatography; ion-exchange chromatography; size exclusion chromatography; electrophoretic procedures (e.g., preparative isoelectric focusing (IEF), differential solubility (e.g., ammonium sulfate precipitation), or extrac- tion and the like, as described in more detail above.
  • the preparation preferably contains less than about 10% by weight, more preferably less than about 5% and most preferably less than about 1 %, of non-aprotinin or aprotinin-related polypeptides derived from the host cell.
  • the resulting activated aprotinin or aprotinin-related polypeptide may then be formulated and administered as described below.
  • the preparations of the present invention may be used to treat any factor VII responsive syndrome, such as, e.g., bleeding disorders, including, without limitation, syndromes caused by a reduced level of clotting factors VIII, IX, XI or VII, clotting factor inhibitors, defective platelet function (e.g., Glanzmann thombasthenia and Bernard-Soulier syndrome), thrombocytopenia, von Willebrand's disease, and coagulophathy such as that caused by a dilution of coagulation proteins, increased fibrinolysis and lowered number of platelets due to bleedings and/or transfusions (e.g., in multi transfused subjects having been subjected to surgery or trauma).
  • factor VII responsive syndrome such as, e.g., bleeding disorders, including, without limitation, syndromes caused by a reduced level of clotting factors VIII, IX, XI or VII, clotting factor inhibitors, defective platelet function (e.g., Glanzmann thombasthenia and
  • compositions comprising a preparation of factor VII or a factor Vll-related polypeptide and a preparation of aprotinin or a aprotinin-related polypeptide according to the present invention are primarily intended for parenteral administration for prophylactic and/or therapeutic treatment.
  • the pharmaceutical compositions are administered parenterally, i.e., intravenously, subcutaneously, or intramuscularly; intravenously being most preferred. They may also be administered by continuous or pulsatile infusion.
  • compositions or formulations according to the invention comprise a factor VII or a factor Vll-related polypeptide, and aprotinin or a aprotinin-related polypeptide, either formulated in a single-unit dosage form or in the form of a kit-of parts, preferably dissolved in, a pharmaceutically acceptable carrier, preferably an aqueous carrier or diluent.
  • compositions suitable for use according to the present invention is made by mixing factor VII or a factor Vll-related polypeptide, or a aprotinin, or factor VII or a factor Vll-related polypeptide in combination with a aprotinin, preferably in purified form, with suitable adjuvants and a suitable carrier or diluent.
  • suitable adjuvants and a suitable carrier or diluent.
  • aqueous carriers may be used, such as water, buffered water, 0.4% saline, 0.3% glycine and the like.
  • the preparations of the invention can also be formulated using non-aqueous carriers, such as, e.g., in the form of a gel or as liposome preparations for delivery or targeting to the sites of injury.
  • Liposome preparations are generally described in, e.g., U.S. Patents Nos. 4,837,028, 4,501,728, and 4,975,282.
  • the compositions may be sterilised by conventional, well-known sterilisation techniques.
  • the resulting aqueous solutions may be packaged for use or filtered under aseptic conditions and lyophilised, the lyophilised preparation being combined with a sterile aqueous solution prior to administration.
  • compositions may contain pharmaceutically acceptable auxiliary substances or adjuvants, including, without limitation, pH adjusting and buffering agents and/or tonicity adjusting agents, such as, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc.
  • pH adjusting and buffering agents and/or tonicity adjusting agents such as, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc.
  • Formulations may further include one or more diluents, emulsifiers, preservatives, buffers, excipients, etc. and may be provided in such forms as liquids, powders, emulsions, controlled release, etc.
  • diluents such as those disclosed in Remington's Pharmaceutical Sciences. Gennaro, ed., Mack Publishing Co., Easton, PA, 1990.
  • a typical pharmaceutical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution and 10 mg of the preparation.
  • the compositions containing the preparations of the present invention can be administered for prophylactic and/or therapeutic treatments.
  • compositions are administered to a subject already suffering from a disease, as described above, in an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of the disease and its complications.
  • An amount adequate to accomplish this is defined as "therapeutically effective amount” .
  • Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix.
  • Local delivery of the preparations of the present invention may be carried out, e.g., by means of a spray, perfusion, double balloon catheters, stent, incorporated into vascular grafts or stents, hydrogels used to coat balloon catheters, or other well established methods.
  • the pharmaceutical compositions should provide a quantity of the preparation sufficient to effectively treat the condition.
  • the concentration of factor VII or factor Vll-related polypeptide, aprotinin or aprotinin- related polypeptide, or factor VII or factor Vll-related polypeptide in combination with aprotinin or aprotinin-related polypeptide in these formulations can vary widely, i.e., from less than about 0.5% by weight, usually at or at least about 1 % by weight to as much as 15 or 20% by weight and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected. Administration by injection or infusion, in particular injection, is preferred.
  • the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin- related polypeptide are prepared in a form suitable for intravenous administration, such as a preparation that is either a dissolved lyophilized powder or a liquid formulation containing both the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide in one dosage form, or a dissolved lyophilized powder or a liquid formulation containing the factor VII or factor Vll-related polypeptide in one dosage form and dissolved lyophilized powder or a liquid formulation containing the aprotinin or aprotinin-related polypeptide in another dosage form.
  • the amount of factor VII or factor Vll-related polypeptide and the amount of aprotinin or aprotinin-related polypeptide together comprise an aggregate effective amount for treating the bleeding episode.
  • compositions containing a preparation of factor VII or a factor Vll-related polypeptide and a preparation of aprotinin or a aprotinin-related polypeptide are administered to a subject susceptible to or otherwise at risk of a disease state or injury to enhance the subject's own coagulative capability.
  • Such an amount is defined to be a “prophylactically effective dose.” It is to be understood that the amount of factor VII or factor Vll-related polypeptide and the amount of aprotinin or aprotinin-related polypeptide together comprise an aggregate effective amount for preventing a bleeding episode.
  • compositions can be carried out with dose levels and patterns being selected by the treating physician.
  • the compositions may be administered one or more times per day or week.
  • An effective amount of such a pharmaceutical composition is the amount that provides a clinically significant effect against bleeding episodes. Such amounts will depend, in part, on the particular condition to be treated, age, weight, and general health of the subject, and other factors evident to those skilled in the art.
  • composition of the invention is generally administered in a single dose before the expected bleeding or at the start of the bleeding. It may however also be given repeatedly (in multiple doses) preferably with intervals of 2-4-6-12 hour, depending on the dose given and the condition of the subject.
  • the factor VII or factor Vll- related polypeptide and the aprotinin or aprotinin-related polypeptide will typically be administered within about 24 hours prior to performing the intervention, and for as much as 7 days or more thereafter.
  • Administration as a coagulant can be by a variety of routes as described herein.
  • the composition may be in the form of a single preparation (single-dosage form) comprising both a preparation of a preparation of factor VII or a factor Vll-related polypeptide and a preparation of a preparation of aprotinin or a aprotinin-related polypeptide in suitable concentrations.
  • the composition may also be in the form of a kit-of-parts consisting of a first unit dosage form comprising a preparation of a preparation of factor VII or a factor Vll-related polypeptide and a second unit dosage form comprising a preparation of a preparation of aprotinin or a aprotinin-related polypeptide.
  • the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide should be administered one after the other, preferably within about 15 minutes of each other, for example within 10 minutes of each other or, preferably, within 5 minutes or, more preferred, within 2 minutes of each other. Either of the two unit dosage forms can be administered first.
  • the kit includes at least two separate pharmaceutical compositions.
  • the kit includes container means for containing the separate compositions such as a divided bottle or a divided foil packet.
  • the kit includes directions for the administration of the separate components.
  • the kit form is particularly advantageous when the separate components are preferably administered in different dosage forms, are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.
  • the amount of factor VII or factor Vll-related polypeptide and the amount of aprotinin or aprotinin-related polypeptide administered according to the present invention may vary from a ratio of between about 1 :100 to about 100:1 (w/w).
  • the ratio of factor VII to aprotinin may thus be, e.g., about 1 :100, or 1 :90, or 1:80, or 1:70 or 1:60, or 1:50, or 1:40, or 1 :30, or 1 :20, or 1 :10, or 1:5, or 1:2, or 1:1, or 2:1, or 5:1, or 10:1, or 20:1, or 30.1, or 40:1, or 50:1, or 60:1, or 70:1, or 80:1, or 90:1, or 100:1; or between about 1 :90 to about 1 :1, or between about 1 :80 to about 1:2, or between about 1 :70 to about 1 :5, or between about 1 :60 to about 1 :10, or between about 1 :50 to about 1 :25, or between about 1:40 to about 1 :30, or between about 90:1 to about 1 :1, or between about 80:1 to about 2:1, or between about 70:1 to about 5:1, or between about 60:1 to about 10
  • the dose of the factor VII or factor Vll-related polypeptide ranges from what corresponds to about 0.05 mg to about 500 mg/day of wild-type factor VII, e.g., from about 1 mg to about 200 mg/day, or, e.g., from about 5 mg to about 175 mg/day for a 70-kg subject as loading and maintenance doses, depending on the weight of the subject, the condition and the severity of the condition.
  • the dose of the aprotinin or aprotinin-related polypeptide ranges from what corresponds to about 0.05 mg to about 500 mg/day of wild-type aprotinin, e.g., from about 1 mg to about 200 mg/day, or, e.g., from about 1 mg to about 175 mg/day for a 70-kg subject as loading and maintenance doses, depending on the weight of the subject, the condition and the severity of the condition.
  • the combination of factor Vila and a aprotinin shows a synergistic effect in an in vitro clot firmness- and fibrinolysis time-assay.
  • the combination of factor VII or a factor Vll- related polypeptide and a aprotinin shows a synergistic effect in forming stable fibrin clots, increasing the half-clot lysis time, increasing clot strength and increasing resistance to fibrinolysis.
  • the composition may be in the form of a single preparation comprising both factor VII or a factor Vll-related polypeptide and a aprotinin in suitable concentrations.
  • the composition may also be in the form of a kit consisting of a first unit dosage form comprising factor VII or a factor VII- related polypeptide, and a second unit dosage form comprising aprotinin or a aprotinin-related polypeptide.
  • the factor VII or factor Vll-related polypeptide and the aprotinin or aprotinin-related polypeptide should be administered sequentially, preferably within about 1-2 hours of each other, for example within 30 minutes of each other or, preferably, within 10 minutes or, more preferred, within 5 minutes of each other. Either of the two unit dosage forms can be administered first.
  • the present invention relates to the prevention or treatment of bleeding episodes or for coagulative treatment by treatment with a combination of active ingredients that may be administered separately
  • the invention also relates to combining separate pharmaceutical compositions in kit form.
  • the kit includes at least two separate pharmaceutical compositions.
  • the kit includes container means for containing the separate compositions such as a divided bottle or a divided foil packet.
  • the kit includes directions for the administration of the separate components.
  • the kit form is particularly advantageous when the separate components are preferably administered in different dosage forms, are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician
  • a suitable assay for testing for factor Vila activity and thereby selecting suitable factor Vila variants can be performed as a simple preliminary in vitro test: In Vitro Hydrolysis Assay
  • Native (wild-type) factor Vila and factor Vila variant may be assayed for specific activities. They may also be assayed in parallel to directly compare their specific activities.
  • the assay is carried out in a microtiter plate (MaxiSorp, Nunc, Denmark).
  • the ab- sorbance at 405 nm is measured continuously in a SpectraMaxTM 340 plate reader (Molecular Devices, USA).
  • the absorbance developed during a 20-minute incubation, after subtraction of the absorbance in a blank well containing no enzyme, is used to calculate the ratio between the activities of variant and wild-type factor Vila:
  • Ratio (A 40 5 nm factor Vila variant)/(A 405 n factor Vila wild-type). Based thereon, factor Vila variants with an activity comparable to or higher than native factor Vila may be identified, such as, for example, variants where the ratio between the activity of the variant and the activity of native factor VII (wild-type FVII) is around, versus above 1.0.
  • the activity of factor Vila or factor Vila variants may also be measured using a physiological substrate such as factor X, suitably at a concentration of 100-1000 nM, where the factor Xa generated is measured after the addition of a suitable chromogenic substrate (eg. S-2765).
  • the activity assay may be run at physiological temperature.
  • factor Vila Native (wild-type) factor Vila and factor Vila variant (both hereafter referred to as "factor Vila") are assayed in parallel to directly compare their specific activities.
  • the assay is carried out in a microtiter plate (MaxiSorp, Nunc, Denmark), factor Vila (10 nM) and factor X (0.8 mi- croM) in 100 microL 50 mM Hepes, pH 7.4, containing 0.1 M NaCl, 5 mM CaCl2 and 1 mg/ml bovine serum albumin, are incubated for 15 min.
  • factor X cleavage is then stopped by the addition of 50 microL 50 mM Hepes, pH 7.4, containing 0.1 M NaCl, 20 mM EDTA and 1 mg/ml bovine serum albumin.
  • the amount of factor Xa generated is measured by addition of the chromogenic substrate Z-D-Arg-Gly-Arg-p-nitroanilide (S-2765, Chromogenix, Sweden), final concentration 0.5 mM.
  • the absorbance at 405 nm is measured continuously in a SpectraMaxTM 340 plate reader
  • Ratio (A405 nm factor Vila variant)/(A405 nm factor Vila wild-type). Based thereon, factor Vila variants with an activity comparable to or higher than native factor Vila may be identified, such as, for example, variants where the ratio between the activity of the variant and the activity of native factor VII (wild-type FVII) is around, versus above 1.0.
  • Thrombin generation assay The ability of factor VII or factor Vll-related polypeptides or aprotinin or aprotinin- related polypeptides (e.g., variants) to generate thrombin can be measured in an assay comprising all relevant coagulation factors and inhibitors at physiological concentrations and activated platelets (as described on p. 543 in Monroe et al. (1997) Brit. J. Haematol. 99, 542-547 which is hereby incorporated as reference).
  • Suitable assays for testing for aprotinin activity can be performed as simple in vitro tests as described in the examples herein, or in vitro assays measuring serine protease inhibition or other assays known in the art.
  • Suitable amidolytic and immunosorbent assays are for example described in Cardigan et al., Blood Coagulation & Fibrinolysis 2001; 12:37-42. (the "aprotinin assay")
  • the present invention is further illustrated by the following examples, which, however, are not to be construed as limiting the scope of protection.
  • the features disclosed in the fore- going description and in the following examples may, both separately and in any combination thereof, be material for realizing the invention in diverse forms thereof .
  • RESULTS Clot lysis assay: Normal human plasma diluted 10-fold with buffer (20 mM HEPES, 150 mM NaCl, 5 mM CaCl, pH 7.4) containing Innovin (Dade Behring, 2000-fold dilution), rFVIIa (Novo Nordisk A/S, Bagsvaerd, Denmark; various concentrations) and t-PA (American Diagnostics, 8 nM) was added to 96-well ELISA plates and turbidity at 650 nm was measured over time at room temperature. Where indicated, purified aprotinin (Novo Nordisk A/S, Bagsvaerd, Denmark) was included.
  • Rotatonal thromboelastography Measurements was conducted on citrated normal human plasma or Factor VIII deficient plasma (George King Bio-Medical, Inc. #0800) added 5 nM t- PA and the effect of addition of 1 nM FVIIa alone or in combination with aprotinin was analyzed. Clotting was initiated by addition of Innovin (final concentration 2000-fold diluted, Dade Behring # 526945) and calcium (final concentration 15 mM) in a 20 mM HEPES, 150 mM NaCl, pH 7.4 buffer.
  • Clot lysis assay Addition of FVIIa results in a dose-dependent prolongation of the clot lysis time (Fig. 1). This effect was optimal at 10 nM FVIIa. In the presence of 10 nM FVIIa, addition of aprotinin resulted in a further prolongation of the clot lysis time (Fig. 2). The effect was dose- dependent and optimal at 1 ⁇ M aprotinin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

la présente invention concerne une composition comprenant le facteur VII ou un polypeptides associé au facteur VII et de l'aprotinine ou un polypeptide associé à l'aprotinine ainsi que son utilisation pour le traitement des épisodes hémorragiques.
EP02774481A 2001-11-09 2002-11-05 Composition pharmaceutique comportant des polypeptides du facteur vii et des polypeptides d'aprotinine Withdrawn EP1446155A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101668 2001-11-09
DK200101668 2001-11-09
PCT/DK2002/000742 WO2003039590A1 (fr) 2001-11-09 2002-11-05 Composition pharmaceutique comportant des polypeptides du facteur vii et des polypeptides d'aprotinine

Publications (1)

Publication Number Publication Date
EP1446155A1 true EP1446155A1 (fr) 2004-08-18

Family

ID=8160826

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02774481A Withdrawn EP1446155A1 (fr) 2001-11-09 2002-11-05 Composition pharmaceutique comportant des polypeptides du facteur vii et des polypeptides d'aprotinine

Country Status (3)

Country Link
EP (1) EP1446155A1 (fr)
JP (1) JP2005508985A (fr)
WO (1) WO2003039590A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9617259B2 (en) 2013-03-14 2017-04-11 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
US9783488B2 (en) 2013-03-14 2017-10-10 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
US10065948B2 (en) 2014-06-02 2018-09-04 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0302052A3 (en) 1999-07-14 2005-12-28 Novo Nordisk Healthcare Ag Use of fviia or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
EP2392655A3 (fr) 2003-09-09 2012-02-29 Novo Nordisk Health Care AG Polypeptides de facteur VII à coagulation
JP2007520530A (ja) * 2004-02-05 2007-07-26 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 外傷の遅発型合併症の治療のための、ＶＩＩａ因子又はＶＩＩａ因子等価物の使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02167234A (ja) * 1988-07-14 1990-06-27 Furukawa Fuaamashii:Kk 生体組織接着剤
WO1993006855A1 (fr) * 1991-10-11 1993-04-15 Novo Nordisk A/S Composition hemostatique pour hemostase locale
AU2001254624A1 (en) * 2000-05-03 2001-11-12 Novo-Nordisk A/S Human coagulation factor vii variants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03039590A1 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9617259B2 (en) 2013-03-14 2017-04-11 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
US9783488B2 (en) 2013-03-14 2017-10-10 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
US10106535B2 (en) 2013-03-14 2018-10-23 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
US10065948B2 (en) 2014-06-02 2018-09-04 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
US10457675B2 (en) 2014-06-02 2019-10-29 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof

Also Published As

Publication number Publication date
JP2005508985A (ja) 2005-04-07
WO2003039590A1 (fr) 2003-05-15

Similar Documents

Publication Publication Date Title
US20050267014A1 (en) Pharmaceutical composition comprising factor VII polypeptides and tranexamic acid
US20080058266A1 (en) Pharmaceutical Compositions Comprising Factor VII Polypeptides and Factor XI Polypeptides
US7078479B2 (en) Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US20080069810A1 (en) Pharmaceutical Composition Comprising Factor VII Polypeptides and TAFI Polypeptides
EP1446150A1 (fr) Composition pharmaceutique contenant des polypeptides associes au facteur vii et des inhibiteurs de la proteine c
US20070219135A1 (en) Pharmaceutical Composition Comprising Factor VII Polypeptides and PAI-1 Polypeptide
US20030119743A1 (en) Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
AU2002354846B2 (en) Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US20030119741A1 (en) Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides
WO2003039582A1 (fr) Composition pharmaceutique comprenant un poylpeptide de facteur vii et un acide epsilon-aminocapronique
AU2002354846A1 (en) Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US20080075709A1 (en) Pharmaceutical Composition Comprising Factor VII Polypeptides And Thrombomodulin Polypeptides
US20060025336A1 (en) Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
EP1446155A1 (fr) Composition pharmaceutique comportant des polypeptides du facteur vii et des polypeptides d'aprotinine
AU2002340779A1 (en) Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
WO2003039584A1 (fr) Composition pharmaceutique comprenant des polypeptides de facteur vii et des polypeptides de facteur v
AU2002340778B2 (en) Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
WO2003039581A1 (fr) Composition pharmaceutique comprenant des polypeptides du facteur vii et de l'acide tranexamique
WO2003039579A1 (fr) Composition pharmaceutique comprenant un polypeptide de facteur vii et un polypeptide tafi
AU2002340778A1 (en) Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
EP1446153A1 (fr) Composition pharmaceutique renfermant des polypeptides de facteur vii et des inhibiteurs du plasminogene tissulaire
WO2003039589A1 (fr) Composition pharmaceutique comprenant des polypeptides de facteur vii et des polypeptides alpha2-antiplasmines
WO2003039586A1 (fr) Composition pharmaceutique comprenant des polypeptides de facteur vii et des polypeptides de thrombomoduline

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20041015

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVO NORDISK HEALTH CARE AG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20070111